Addex Therapeutics Ltd (ADXN) Financial Statements
Addex Therapeutics Ltd (ADXN) files with the U.S. Securities and Exchange Commission under CIK 0001574232. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2025
- Revenue
- 29.97 thousand CHF
- Net Income
- -6.73 million CHF
- Total Assets
- 6.36 million CHF
- Net Cash from Operations
- -2.17 million CHF
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: May 15, 2026. Source: SEC filings (EDGAR XBRL). Amounts in CHF.
Open the full financial statements for ADXN in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History